Please login to the form below

Not currently logged in
Email:
Password:

LigoCyte

This page shows the latest LigoCyte news and features for those working in and with pharma, biotech and healthcare.

Takeda starts trial of norovirus vaccine

Takeda starts trial of norovirus vaccine

Takeda acquired rights to TAK-214 when it bought US biopharma company LigoCyte in 2012 in a $60m deal and says it remains the only norovirus vaccine candidate in clinical development.

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    The LigoCyte acquisition is part of the expansion of Takeda's recently formed Vaccine Business Division. ... 90+. ‡Theravance / Alfa Wasserman. Development, commercialisation &option. Velusetrag for gastroparesis (phase IIa)  . 64. LigoCyte /Takeda.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics